The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.
The company recently met with the FDA and believes that the agency no longer considers the data from an early-to-mid-stage trial of its investigational gene therapy sufficient for approval.
The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.
Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.